TY - JOUR
T1 - Longitudinal association of antidepressant medication use with metabolic syndrome
T2 - Results of a 9-year follow-up of the D.E.S.I.R. cohort study
AU - Azevedo Da Silva, Marine
AU - Balkau, Beverley
AU - Roussel, Ronan
AU - Tichet, Jean
AU - Fumeron, Frédéric
AU - Fagherazzi, Guy
AU - Nabi, Hermann
AU - D.E.S.I.R. study group
N1 - Funding Information:
MADS is the recipient of a doctoral fellowship from the Ministère de l’Enseignement Supérieur et de la Recherche, Paris, France.
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Objective To examine longitudinal associations between antidepressant medication use and the metabolic syndrome (MetS). Methods 5014 participants (49.8% were men) from the D.E.S.I.R. cohort study, aged 30–65 years at baseline in 1994–1996, were followed over 9 years at 3-yearly intervals (1997–1999, 2000–2002, and 2003–2005). Antidepressant use and MetS, defined by the National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP-ATP III) and the American Heart Association and the National Heart, Lung and Blood Institute (AHA/NHLBI) criteria, were assessed concurrently at four medical examinations. Results In fully-adjusted longitudinal logistic regression analyses based on generalized estimating equations, antidepressant users had a 9% (p = 0.011) and a 6% (p = 0.036) greater annual increase in the odds of having the MetS defined by NCEP-ATP III and AHA/NHLBI criteria respectively. Sex-specific analyses showed that this association was confined to men only. When the different types of antidepressant were considered, men who used selective serotonin reuptake inhibitors (SSRIs), imipramine type antidepressants or “other” antidepressants had a 52% (p = 0.028), 31% (p = 0.011), and 16% (p = 0.016) greater annual increase in the odds of having the MetS over time compared to non-users, respectively. These associations depended on the definition of the MetS. Conclusions Our longitudinal data showed that antidepressant use was associated with an increased odds of having the MetS in men but not in women and this was mainly for SSRIs, imipramine type and “other” antidepressants. People on antidepressants may need to be checked regularly for the elements of the metabolic syndrome treatable by change in diet, physical activity and/or by medication therapy.
AB - Objective To examine longitudinal associations between antidepressant medication use and the metabolic syndrome (MetS). Methods 5014 participants (49.8% were men) from the D.E.S.I.R. cohort study, aged 30–65 years at baseline in 1994–1996, were followed over 9 years at 3-yearly intervals (1997–1999, 2000–2002, and 2003–2005). Antidepressant use and MetS, defined by the National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP-ATP III) and the American Heart Association and the National Heart, Lung and Blood Institute (AHA/NHLBI) criteria, were assessed concurrently at four medical examinations. Results In fully-adjusted longitudinal logistic regression analyses based on generalized estimating equations, antidepressant users had a 9% (p = 0.011) and a 6% (p = 0.036) greater annual increase in the odds of having the MetS defined by NCEP-ATP III and AHA/NHLBI criteria respectively. Sex-specific analyses showed that this association was confined to men only. When the different types of antidepressant were considered, men who used selective serotonin reuptake inhibitors (SSRIs), imipramine type antidepressants or “other” antidepressants had a 52% (p = 0.028), 31% (p = 0.011), and 16% (p = 0.016) greater annual increase in the odds of having the MetS over time compared to non-users, respectively. These associations depended on the definition of the MetS. Conclusions Our longitudinal data showed that antidepressant use was associated with an increased odds of having the MetS in men but not in women and this was mainly for SSRIs, imipramine type and “other” antidepressants. People on antidepressants may need to be checked regularly for the elements of the metabolic syndrome treatable by change in diet, physical activity and/or by medication therapy.
KW - AHA/NHLBI
KW - Antidepressant
KW - Cohort study
KW - Metabolic syndrome
KW - NCEP-ATP III
KW - Prospective study
UR - http://www.scopus.com/inward/record.url?scp=84983550754&partnerID=8YFLogxK
U2 - 10.1016/j.psyneuen.2016.08.020
DO - 10.1016/j.psyneuen.2016.08.020
M3 - Article
C2 - 27567119
AN - SCOPUS:84983550754
SN - 0306-4530
VL - 74
SP - 34
EP - 45
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
ER -